v3.26.1
Agreements with Royalty Pharma (Tables)
3 Months Ended
Mar. 31, 2026
Debt Instrument [Line Items]  
Summary of Changes of the Fair Value of Liabilities

The following tables summarize the changes of the fair value of the RP Ulacamten RPA and RP OM Loan (in thousands):

 

 

2026

 

 

2025

 

 

 

RP Ulacamten RPA

 

 

RP OM Loan

 

 

RP Ulacamten RPA

 

 

RP OM Loan

 

Beginning balance, January 1

 

$

13,700

 

 

$

123,500

 

 

$

14,000

 

 

$

123,000

 

Change in fair value

 

 

(200

)

 

 

1,800

 

 

 

(300

)

 

 

(3,600

)

Ending balance, March 31

 

$

13,500

 

 

$

125,300

 

 

$

13,700

 

 

$

119,400

 

Schedule of Activity within Liabilities Related to Sale of Future Royalties Changes to the RP Aficamten Liability and the RP OM Liability are as follows (in thousands):

 

 

2026

 

 

2025

 

 

 

RP Aficamten Liability

 

 

RP OM Liability

 

 

RP Aficamten Liability

 

 

RP OM Liability

 

Beginning balance, January 1

 

$

320,764

 

 

$

199,795

 

 

$

262,599

 

 

$

199,593

 

Interest accretion

 

 

18,816

 

 

 

 

 

 

14,037

 

 

 

41

 

Amortization of issuance costs

 

 

 

 

 

 

 

 

 

 

 

26

 

Ending balance, March 31

 

$

339,580

 

 

$

199,795

 

 

$

276,636

 

 

$

199,660

 

Summary of Changes of Fair Value of Derivative Liabilities

The following table summarizes the changes of the fair value of the derivative liabilities for the RP Multi Tranche Loan Agreement (in thousands):

 

 

RP Multi Tranche Loan Agreement Derivatives

 

 

 

2026

 

 

2025

 

Beginning balance, January 1

 

$

31,100

 

 

$

11,300

 

Change in fair value

 

 

(1,500

)

 

 

400

 

Ending balance, March 31

 

$

29,600

 

 

$

11,700